Abstract
Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p
| Original language | English |
|---|---|
| Pages (from-to) | 348-356 |
| Number of pages | 9 |
| Journal | Journal of Hepatology |
| Volume | 53 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Aug 2010 |
Fingerprint
Keywords
- Antivirals
- Hepatitis B
- Hepatocellular carcinoma
- Lamivudine
- Nucleoside analogues
- Nucleotide analogues
ASJC Scopus subject areas
- Hepatology
- Medicine(all)
Cite this
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy : A systematic review. / Papatheodoridis, George V.; Lampertico, Pietro; Manolakopoulos, Spilios; Lok, Anna.
In: Journal of Hepatology, Vol. 53, No. 2, 08.2010, p. 348-356.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy
T2 - A systematic review
AU - Papatheodoridis, George V.
AU - Lampertico, Pietro
AU - Manolakopoulos, Spilios
AU - Lok, Anna
PY - 2010/8
Y1 - 2010/8
N2 - Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p
AB - Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p
KW - Antivirals
KW - Hepatitis B
KW - Hepatocellular carcinoma
KW - Lamivudine
KW - Nucleoside analogues
KW - Nucleotide analogues
UR - http://www.scopus.com/inward/record.url?scp=77955306935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955306935&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2010.02.035
DO - 10.1016/j.jhep.2010.02.035
M3 - Article
C2 - 20483498
AN - SCOPUS:77955306935
VL - 53
SP - 348
EP - 356
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 2
ER -